182 related articles for article (PubMed ID: 28445481)
41. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Ambati SR; Shieh JH; Pera B; Lopes EC; Chaudhry A; Wong EW; Saxena A; Su TL; Moore MA
Oncotarget; 2016 Jul; 7(28):43062-43075. PubMed ID: 27248664
[TBL] [Abstract][Full Text] [Related]
42. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
Alexander HR; Libutti SK; Pingpank JF; Bartlett DL; Helsabeck C; Beresneva T
Ann Surg Oncol; 2005 Feb; 12(2):138-44. PubMed ID: 15827794
[TBL] [Abstract][Full Text] [Related]
43. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
[TBL] [Abstract][Full Text] [Related]
44. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
45. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
46. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
47. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
[TBL] [Abstract][Full Text] [Related]
48. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Makondi PT; Chu CM; Wei PL; Chang YJ
PLoS One; 2017; 12(7):e0180616. PubMed ID: 28749961
[TBL] [Abstract][Full Text] [Related]
49. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
51. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
52. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
53. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
[TBL] [Abstract][Full Text] [Related]
54. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
[TBL] [Abstract][Full Text] [Related]
55. Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
Barone C; Landriscina M; Quirino M; Basso M; Pozzo C; Schinzari G; Di Leonardo G; D'Argento E; Trigila N; Cassano A
Br J Cancer; 2007 Jan; 96(1):21-8. PubMed ID: 17164761
[TBL] [Abstract][Full Text] [Related]
56. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Ho C; Ng K; O'Reilly S; Gill S
Clin Colorectal Cancer; 2005 Nov; 5(4):279-82. PubMed ID: 16356306
[TBL] [Abstract][Full Text] [Related]
57. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
[TBL] [Abstract][Full Text] [Related]
58. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Osuga T; Takimoto R; Ono M; Hirakawa M; Yoshida M; Okagawa Y; Uemura N; Arihara Y; Sato Y; Tamura F; Sato T; Iyama S; Miyanishi K; Takada K; Hayashi T; Kobune M; Kato J
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628655
[TBL] [Abstract][Full Text] [Related]
59. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
[TBL] [Abstract][Full Text] [Related]
60. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
